Disease Detail

ID DOID:2994
Name germ cell cancer
Definition A cell type cancer that has_material_basis_in abnormally proliferating cells derives_from germ cells.
Source DiseaseOntology.org
Alt Ids DOID:2157
Path disease disease of cellular proliferation cancer cell type cancer germ cell cancer

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
KIT positive Imatinib germ cell cancer resistant detail...
Unknown unknown Pazopanib germ cell cancer not applicable detail...
Unknown unknown Ipafricept germ cell cancer not applicable detail...
Clinical Trial Phase Therapies Title Recruitment Status
NCT00936936 Phase II Gemcitabine Ifosfamide Etoposide Melphalan Etoposide + Ifosfamide Docetaxel + Gemcitabine + Melphalan Bevacizumab + Carboplatin High-dose Chemotherapy for Poor-prognosis Relapsed Germ-Cell Tumors Active, not recruiting
NCT00983398 Phase Ib/II Pegfilgrastim Filgrastim Carboplatin + Melphalan Melphalan, Carboplatin, and Sodium Thiosulfate for Patients With Central Nervous System (CNS) Embryonal or Germ Cell Tumors Suspended
NCT01037790 Phase II Palbociclib PHASE II TRIAL OF THE CYCLIN-DEPEDENT KINASE INHIBITOR PD 0332991 IN PATIENTS WITH CANCER Recruiting
NCT01331135 Phase I Sirolimus Aflac ST0901 CHOANOME - Sirolimus in Solid Tumors Active, not recruiting
NCT01625351 Phase I Fludarabine Melphalan Busulfan Alemtuzumab A Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children With Relapsed or Refractory Solid Tumors and Lymphomas Active, not recruiting
NCT01962896 Phase II Erlotinib + Sirolimus A Phase II Study of Sirolimus and Erlotinib in Recurrent/Refractory Germ Cell Tumors Terminated
NCT02034110 Phase II Dabrafenib + Trametinib Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers Active, not recruiting
NCT02130869 Phase I Bendamustine + Cytarabine + Etoposide Busulfan + Hu14.18K322A Aldesleukin + Melphalan + Sargramostim Filgrastim Carboplatin + Etoposide A Pilot Study of Immunotherapy Including Haploidentical NK Cell Infusion Following CD133+ Positively-Selected Autologous Hematopoietic Stem Cells in Children With High Risk Solid Tumors or Lymphomas Completed
NCT02300987 Phase II Ribociclib A Randomized, Blinded, Placebo-controlled, Phase II Trial of LEE011 in Patients With Relapsed, Refractory, Incurable Teratoma With Recent Progression Completed
NCT02429466 Phase I Cisplatin Guadecitabine Study of the Hypomethylating Drug SGI-110 Plus Cisplatin in Relapsed Refractory Germ Cell Tumors Suspended
NCT02454972 Phase II Lurbinectedin Clinical Trial of Lurbinectedin (PM01183) in Selected Advanced Solid Tumors Active, not recruiting
NCT02499952 Phase II Pembrolizumab Pembrolizumab in Subjects With Incurable Platinum-Refractory Germ Cell Tumors Terminated
NCT02839694 Phase I Decitabine + Tetrahydrouridine Celecoxib + Decitabine + Tetrahydrouridine Adjuvant Oral Decitabine and Tetrahydrouridine With or Without Celecoxib in People Undergoing Pulmonary Metastasectomy Withdrawn
NCT02988843 Phase II Bevacizumab + Brentuximab vedotin Study of Brentuximab Vedotin And Bevacizumab In Refractory CD-30 Positive Germ Cell Tumors Suspended
NCT03158064 Phase II Durvalumab + Tremelimumab Evaluating Immune Therapy, Duravalumab (MEDI4736) With Tremelimumab for Relapsed/Refractory Germ Cell Tumors Active, not recruiting
NCT03333616 Phase II Ipilimumab + Nivolumab Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors Recruiting
NCT03698994 Phase II Ulixertinib Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial) Recruiting